Storys zum Thema Medicale

16.11.2016 – 18:14
Grünenthal Group
Grünenthal has acquired US-based Thar Pharmaceuticals Inc. to expand its development portfolio of treatment options for CRPS (Complex Regional Pain Syndrome), a serious, disabling orphan disease
Aachen, Germany / Pittsburgh, PA, USA (ots) - - The acquisition supports Grünenthal's commercial and R&D strategy to drive innovation in pain. - Thar Pharmaceutical's lead compound, T121, complements Grünenthal's existing development pipeline and the goal of delivering innovative and effective treatments to ...
mehr
12.11.2016 – 13:01
Shire Pharmaceuticals Group Plc
Tolerability Data for Shire's CUVITRU Accepted for Oral Presentation at the American College Of Allergy, Asthma & Immunology Annual Meeting
Lexington, Massachusetts (ots/PRNewswire) - Data reveals key findings on the tolerability of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] for patients, regardless of treatment infusion volume and rates Shire plc (LSE: SHP, NASDAQ: SHPG) will present additional data supporting the tolerability of ...
mehr
12.11.2016 – 09:01
Novo Nordisk
Tresiba® Demonstrated Lower Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Compared With Insulin Glargine U300
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Results from a study comparing the pharmacodynamics of Tresiba® (insulin degludec) with insulin glargine U300 in people with type 1 diabetes were presented ...
mehr
11.11.2016 – 16:02
sanofi-aventis Group
Sanofi Presented Full Results of a PK/PD Study Comparing Toujeo® to Insulin Degludec in People With Type 1 Diabetes
Paris (ots/PRNewswire) - - Toujeo® provides a flatter profile than insulin degludec with less within-day fluctuations - Sanofi (http://www.sanofi.com) presented today the full results of a pharmacokinetic / pharmacodynamic (PK/PD) study with Toujeo® (insulin glargine 300 Units/mL) and insulin degludec 100 Units/mL ...
mehr
03.11.2016 – 15:01
Helsinn Healthcare SA
Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting
Lugano, Switzerland and San Diego (ots/PRNewswire) - Data to be presented on December 3, 2016; Abstract now available online Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel ...
mehr
03.11.2016 – 12:03
Novo Nordisk
New Study Showed That Only 55% of People With Obesity Have Received a Formal Obesity Diagnosis
New Orleans (ots/PRNewswire) - This material is intended for global medial media only. For journalistic assessment and preparation before publication. Abstract #T-P-3178, oral session #T-OR-2088 US study identified multiple barriers to weight management for people living with obesity Divergent perceptions and attitudes about obesity may jeopardise obesity management ...
mehr

02.11.2016 – 14:03
Circ MedTech Ltd
Circ MedTech Donates Three Mobile Clinics to Zimbabwe's National HIV Prevention Program
Harare, Zimbabwe (ots/PRNewswire) - Circ MedTech (http://www.prepex.com/) Ltd., manufacturer of PrePex[TM] - the world's only non-surgical male circumcision device - donated three Mobile Clinics to the Zimbabwe Ministry of Health and Child Care with the aim to support the scale-up of Male Circumcision programs, as part of Zimbabwe's HIV Prevention strategy. (Photo: ...
mehr
01.11.2016 – 09:01
Novo Nordisk
New Data Show Post-Meal Hyperglycaemia is Associated with a Negative Impact on Quality of Life for People with Diabetes
Vienna (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstract: 69477 New data from the first health-related quality of life (HRQL) study related to post-meal or postprandial glucose (PPG) control, show that poor PPG control ...
mehr
31.10.2016 – 08:02
Merck and Pfizer
European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - If approved, avelumab, an investigational anti-PD-L1 IgG1, could be the first treatment indicated for patients with metastatic Merkel cell carcinoma - The Marketing Authorization Application is based on Phase II data from the ...
mehr
28.10.2016 – 09:16
Astellas Pharma EMEA
Astellas to Acquire Ganymed Pharmaceuticals
Tokyo and Mainz, Germany (ots/PRNewswire) - - Acquisition Would Expand Astellas' Oncology Pipeline with Antibody in Late-Stage - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, "Ganymed"), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas ...
mehr
28.10.2016 – 07:01
GfK SE
Eyesight and Memory Loss are Leading Concerns Around Aging
Nuremberg, Germany (ots/PRNewswire) - Internationally, the top five physical conditions that people worry most about having, either now or as they age, are eyesight getting poorer, not being as mentally alert, lacking energy, having trouble taking care of themselves physically, and being unable to walk or drive. These are the findings from a GfK survey (http://www.gfk.com/global-studies/global-study-overview/) of the ...
mehr
27.10.2016 – 20:14
bioLytical Laboratories
bioLytical Participates in Glasgow HIV Drug Therapy Congress
Richmond, British Columbia (ots/PRNewswire) - bioLytical Laboratories, a world leader in rapid infectious disease tests, is proud to have participated in the HIV Drug Therapy Congress (http://hivglasgow.org/) which just wrapped up in Glasgow. This annual Congress brought together key opinion leaders, global HIV/AIDS programme directors, researchers, physicians, community health representatives, industry and other ...
mehr

27.10.2016 – 09:37
Daiichi Sankyo Europe GmbH
World Stroke Day 2016: Research Reveals Delayed Diagnosis Leaves Atrial Fibrillation Patients at Major Stroke Risk
Munich (ots/PRNewswire) - - Atrial fibrillation (AF) increases the risk of a severe stroke,[1] however almost half of patients are unaware of the risk[2] - The AFfect survey revealed that one in two patients had not heard of the condition at time of diagnosis[2] - World Stroke Day is on Saturday 29th October, find ...
mehr
27.10.2016 – 09:03
Daiichi Sankyo Europe GmbH
World Stroke Day 2016: Research Reveals Delayed Diagnosis Leaves Atrial Fibrillation Patients at Major Stroke Risk
Munich (ots/PRNewswire) - - Atrial fibrillation (AF) increases the risk of a severe stroke,[1] however almost half of patients are unaware of the risk[2] - The AFfect survey revealed that one in two patients had not heard of the condition at time of diagnosis[2] - World Stroke Day is on Saturday 29th October, find ...
mehr
25.10.2016 – 10:40
ZikaPLAN
ZikaPLAN: 25 Research Organizations Unite to Fight Zika Virus and Build Long-term Outbreak Response Capacity in Latin America
Recife, Brazil (ots/PRNewswire) - (Logo: http://photos.prnewswire.com/prnh/20161024/431955LOGO ) 25 leading research and public health organizations from Latin America, North America, Africa, Asia, and Europe gathered in Recife for the launch of ZikaPLAN (Zika Preparedness Latin American Network). This global ...
mehr
17.10.2016 – 13:02
Shire Pharmaceuticals Group Plc
Shire Announces Update to Vyvanse® (lisdexamfetamine dimesylate) U.S. Labeling to Include New Longer-Term Maintenance of Efficacy Data in Adults with Moderate to Severe Binge Eating Disorder
Lexington, Massachusetts (ots/PRNewswire) - Labeling Update Based on Maintenance of Efficacy Data from a 38-Week Phase 3 Study For U.S. Audiences Only - Shire plc (LSE: SHP, NASDAQ: SHPG) announces an update to the Vyvanse® (lisdexamfetamine dimesylate) labeling to include information regarding the approval of a ...
mehr
14.10.2016 – 09:01
Astellas Pharma EMEA
World Anti-Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports
Montreal and Tokyo (ots/PRNewswire) - The World Anti-Doping Agency (President: Sir Craig Reedie, "WADA") and Astellas Pharma Inc. (TSE: 4503: President and CEO: Yoshihiko Hatanaka, "Astellas") today announced a global agreement to partner on the prevention of misuse and abuse of medicines for doping in sports. ...
mehr
14.10.2016 – 08:01
BTG plc
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y(TM) Dosimetry Software in Europe
London (ots/PRNewswire) - New easy-to-use software designed to improve the planning of 90Y selective internal radiation therapy (SIRT) treatment for patients with liver cancer BTG plc (LSE: BTG), an international specialist healthcare company, with Mirada Medical Ltd, a leading global brand in medical imaging ...
mehr

13.10.2016 – 09:02
Daiichi Sankyo Europe GmbH
Daiichi Sankyo Announces New Data to be Presented at the ISPOR EU Congress 2016 Analysing the Safety, Efficacy and Cost-effectiveness of LIXIANA® (edoxaban)
Munich (ots/PRNewswire) - - Three abstracts highlight the economic burden of Venous Thromboembolism (VTE) in Europe and provide new insights into VTE treatment with LIXIANA®(edoxaban) - Daiichi Sankyo is committed to enhancing the understanding, prevention and treatment of VTE, and is partnering with the ...
mehr
12.10.2016 – 08:58
HOYA Vision Care
HOYA Corporation Announces Agreement to Acquire Performance Optics, LLC
Tokyo (ots/PRNewswire) - Acquisition strengthens global HOYA Vision Care business HOYA Corporation (HOYA) today announced a definitive agreement to acquire Performance Optics, LLC (Performance Optics), including its subsidiaries VISION EASE and Daemyung Optical. Performance Optics is a global ophthalmic lens manufacturer specializing in polycarbonate, photochromic, ...
mehr
10.10.2016 – 08:15
Merck Healthcare Germany
Merck KGaA, Darmstadt, Germany, Announces Recipients of Third Annual EUR1 Million 'Grant for Oncology Innovation' Award
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media - Grant established by Merck KGaA, Darmstadt, Germany, recognizes pioneering research in personalized treatment of solid tumors - Winners selected by internationally renowned oncologists from 405 applications representing 49 countries Merck KGaA, ...
mehr
10.10.2016 – 08:10
Merck Healthcare Germany
Merck Announces Recipients of Third Annual EUR1 Million 'Grant for Oncology Innovation' Award
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or UK-based media - Grant established by Merck recognizes pioneering research in personalized treatment of solid tumors - Winners selected by internationally renowned oncologists from 405 applications representing 49 countries Merck, a leading science and technology company, today announced the recipients of ...
mehr
10.10.2016 – 08:01
Helsinn Healthcare SA
Helsinn Group Introduces Helsinn Investment Fund
Lugano, Switzerland (ots/PRNewswire) - ~ Helsinn Group creates new investment fund in 40th anniversary year ~ ~ The new fund will focus on supporting early-stage investment opportunities in areas of high unmet patient need ~ Helsinn, the Swiss Pharmaceutical Group focused on building quality cancer care, today introduces Helsinn Investment Fund S.A. ("the Fund"), a fund focused on early-stage investment opportunities in ...
mehr
06.10.2016 – 14:02
Tillotts Pharma AG
Tillotts Pharma AG's Parent Company Zeria Pharmaceutical Receives Approval for Zentacort® 3mg Capsules in Japan
Rheinfelden, Switzerland (ots/PRNewswire) - Zeria Pharmaceutical Co., Ltd. has received the approval for a new drug application for Zentacort 3mg capsules from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the indication of the improvement of Crohn's Disease (CD). Following the acquisition of the ...
mehr

06.10.2016 – 09:01
Greater Paris University Hospitals (AP-HP), Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC), National Cance...
Liver Cancer Researchers from AP-HP and Singapore Collaborate on a Prospective Meta-Analysis of Two Studies of Y-90 resin microspheres versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma (HCC)
Paris and Singapore (ots/PRNewswire) - Cancer researchers from Assistance Publique - Hôpitaux de Paris (AP-HP) and The Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC), National Cancer Centre Singapore (NCCS) and Singapore Clinical Research Institute (SCRI) announced that they will collaborate on a ...
mehr
06.10.2016 – 00:09
Shire Pharmaceuticals Group Plc
Patent Trial and Appeal Board Upholds the Validity of LIALDA® Patent
Lexington, Massachusetts (ots/PRNewswire) - Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Patent & Trademark Office's Patent Trial and Appeal Board (PTAB) has issued their decision upholding the validity of U.S. Patent No. 6,773,720, related to Shire's LIALDA® (mesalamine) product. The petition seeking to institute inter partes review (IPR) was ...
mehr
04.10.2016 – 12:44
Invent Farma and neuraxpharm
Invent Farma and neuraxpharm Appoint New Group CEO
London (ots/PRNewswire) - Following the acquisitions of Invent Farma and neuraxpharm (the "Group") by funds advised by Apax Partners, Stephan Walz has been appointed Chief Executive Officer. He will assume the newly-created role of Group CEO and will be leading Invent Farma's and neuraxpharm's activities across all markets. Until 2015 Mr Walz was the CEO of Aristo, a Germany-headquartered, multi-country pharmaceutical ...
mehr
30.09.2016 – 11:04
Daiichi Sankyo Europe GmbH
New Analysis Shows Maintained Efficacy and Safety of LIXIANA® (edoxaban) in Patients with Acute VTE Requiring a Reduced Dose Based on Clinical Criteria
Munich (ots/PRNewswire) - Results highlight the benefits of reduced dose edoxaban compared to warfarin in a potentially higher risk venous thromboembolism (VTE) patient population[1] Daiichi Sankyo Europe GmbH (hereafter Daiichi Sankyo) today announced data from a new analysis of the phase 3 Hokusai-VTE study, which ...
mehr
30.09.2016 – 10:03
Teva Pharmaceutical Industries Ltd.
EU Marketing Authorization Granted for Teva's Aerivio Spiromax® (fluticasone/salmeterol 500/50)
Amsterdam (ots/PRNewswire) - Approval of hybrid high-dose fluticasone/salmeterol maintenance treatment for people living with severe asthma and COPD, delivered via the award-winning Spiromax® inhaler to help patient usability Teva Pharmaceutical Industries Ltd., announced today that it has received EU Marketing Authorization for Aerivio Spiromax® ...
mehr
28.09.2016 – 12:00
Dornier MedTech GmbH
Protect Your Flexible Scope: New Dornier GentleFlex® Holmium Laser Fiber Delivers the Confidence to Glide Through deflected Scopes
Wessling (ots) - Dornier MedTech®, a global medical device company, introduced their latest innovation in laser lithotripsy. Known as the Dornier GentleFlex®, this is a specially-designed ball tip fiber. The Dornier GentleFlex® smooths the passage of the laser fiber through a deflected scope. The Dornier ...
mehr

Vorherige31323334353637383940Nächste